Clean Energy Firm Powers Up 43% Revenue Growth

Author

Adam Garcia
March 10, 2025

Presented By

A clean energy firm is surging after posting strong revenue growth, a biotech stock is climbing following a major acquisition deal, and an aircraft leasing firm is reporting record revenue and profit growth. Here’s what’s moving the markets today.

📲 Want our updates via text message? Get Elite Trade Club's pre-market insights and hottest stocks straight to your cell for 100% free. Click here to sign up.

Rising Medtech Player (Sponsored)

The medical device market is expected to surge to nearly $890B by 2032, opening massive opportunities for breakthrough technologies.

One emerging company is using perinatal tissue for advanced wound care—attracting growing investor attention.

With quarter-after-quarter revenue growth, a strong patent portfolio, and an anticipated uplisting, this medtech stock could be positioned for a major move.

Futures 📈

What to Watch

Earnings:

  • Oracle Corporation (ORCL): Aftermarket

  • StandardAero, Inc. (SARO): Aftermarket

  • Vail Resorts, Inc. (MTN): Aftermarket

  • Asana, Inc. (ASAN): Aftermarket

  • Paymentus Holdings, Inc. (PAY): Aftermarket

  • Hesai Group (HSAI): Aftermarket

  • HighPeak Energy, Inc. (HPK): Aftermarket

Economic Reports:

  • None scheduled

Pharmaceuticals

BioNTech’s Q4 Income Declines 19% But Beats Analyst Projections

BioNTech SE (NASDAQ: BNTX) reported a decline in fourth-quarter earnings and revenue, though results are ahead of analyst projections.

The company posted a net income of $259.5 million, or $1.08 per share, for the quarter, down from $457.9 million, or $1.88 per share, a year earlier.

Despite the earnings drop, BioNTech’s results are better than Wall Street expectations, as analysts had forecast earnings of $0.37 per share, excluding special items.

Revenue for the quarter fell 19.5% year-over-year, reaching $1.19 billion, compared to $1.48 billion in the same period last year.

The decline reflects lower demand for COVID-19-related products, which had driven previous revenue peaks.

BioNTech continues to focus on expanding its research pipeline, particularly in oncology and infectious diseases, as it works to diversify revenue sources beyond pandemic-related treatments.

The company emphasized upcoming clinical trials and strategic partnerships to support long-term growth.

Clean Energy

NET Power Posts Revenue Increase, Stock Climbs

NET Power Inc. (NASDAQ: NPWR) released its 2024 10-K report today, posting revenue of $250,000, up 43% over the prior year.

Gross profit for the emissions-free natural gas power generation firm is at $219,000, driven by contract earnings and syngas testing at its Demonstration Plant.

Shares of NET Power are up nearly 10% in premarket trade.

However, high operating expenses contributed to a net loss of $164.6 million, with the company’s attributable share of the loss totaling $49.2 million.

Key advancements included upgrades to its 50 MWth Demonstration Plant in Texas and continued development of the SN1 utility-scale facility in the Permian Basin, expected to launch no earlier than 2029.

NET Power also expanded its intellectual property portfolio, holding 485 patents globally.

The company ended 2024 with $530.2 million in liquidity but acknowledges the need for additional capital to fund its first large-scale project.

Future plans for the firm involve securing project-level debt and equity financing.

Energy-saving Solutions (Sponsored)

Wall Street is taking note of a Nasdaq-listed company transforming the $124 billion smart glass industry.

With top clients like Airbus and BMW, a 59% revenue surge in 2023, and energy-saving products, this company could be the next big thing.

Aviation

Willis Lease Finance Achieves Strong Q4 Growth, Revenue Up 33.7%

Willis Lease Finance Corporation (NASDAQ: WLFC) posted record fourth-quarter earnings, with revenue and profit both surpassing prior-year levels.

For Q4, revenue is up 33.7% year-over-year to $152.8 million, while diluted earnings per share have increased to $2.81 from $1.53 a year ago.

The strong performance was driven by rising lease and maintenance revenues, reflecting the company’s ability to capitalize on high-demand aviation assets.

For the full year 2024, Willis Lease Finance reported a total revenue of $569.2 million, marking a record high.

Pre-tax income is at $152.6 million, while lease rent and maintenance reserve revenues climbed 30.4% to $452.1 million.

Lease rent revenue for the quarter grew 24.4% to $64.6 million, while maintenance reserve revenue jumped 54.8% to $57.4 million.

Additionally, the company recorded a gain of $11.9 million from the sale of leased equipment, more than doubling the previous year’s figure.

CEO Austin C. Willis credited the results to strategic asset deployment, noting the company had successfully invested nearly $1 billion in aviation assets.

As of December 31, 2024, Willis Lease Finance’s lease portfolio expanded to $2.87 billion, up from $2.22 billion in 2023.

The company also declared its third consecutive quarterly dividend of $0.25 per share in February 2025.

Movers and Shakers

Redfin Corporation [RDFN] - Last Close: $5.82

Redfin is a digital real estate brokerage firm. The company has struggled with profitability and declining stock value in recent years.

It shares are surging 81.4% in early trade after Rocket Companies (RKT) announced it will acquire Redfin in a $1.75 billion deal.

My Take: Investors see the buyout as a lifeline for Redfin, which has struggled with declining stock value. It remains to be seen how the acquisition plays out. Watch closely for the impact on RKT stock.

Checkpoint Therapeutics, Inc [CKPT] - Last Close: $2.47

Checkpoint Therapeutics is a clinical-stage biotech company focused on targeted treatments for cancer.

Its shares are rising in premarket today after Sun Pharmaceutical Industries announced it would acquire Checkpoint for $4.10 per share in cash, a 66% premium to its last closing price.

My Take: Shareholders may also receive up to $0.70 per share in contingent value rights if Unloxcyt secures European approval, bringing the deal’s potential value to $4.80 per share. Keep an eye on how the acquisition proceeds.

Trevi Therapeutics, Inc. [TRVI] - Last Close: $4.30

Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for serious neurologically mediated conditions.

Shares of the firm are up more than 20% before the opening bell today after Trevi announced that its lead candidate, Haduvio, met its primary endpoint in a mid-stage trial.

With no FDA-approved treatments available for chronic cough of unexplained origin, this success positions Trevi as a potential first-mover in the space.

My Take: This could be a major breakthrough moment for Trevi, so make sure to keep this stock on your radar.

DOGE Watch (Sponsored)

Elon Musk just put Social Security in his crosshairs, claiming his team has uncovered massive fraud inside the agency—including more than 20 million people listed as over 100 years old and even a supposed 360-year-old citizen.

This could be the first step in a radical AI takeover of government agencies—and the companies involved stand to make millions, if not billions.

A new report reveals NINE stocks positioned to soar as AI adoption accelerates—thanks to Elon’s next big move.

Everything Else

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.

*Standard message/carrier rates may apply.

Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website, which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside these emails.